The abstract is read at the publisher; the summary is JClub's.
Venetoclax plus pediatric-inspired chemotherapy in newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia achieved 73.0% measurable residual disease negativity after induction in 167 adolescents and adults.
- Why it matters: The benefit of venetoclax as first-line therapy for newly diagnosed Ph-negative ALL is unclear, leaving a gap in whether it can deepen early MRD responses and improve survival.
- What they did: In a prospective phase 2 trial, 167 patients aged 14–60 received venetoclax with pediatric-inspired chemotherapy, with primary assessment of MFC-based MRD negativity after induction.
- The result: Complete remission was 91.0%, and with median follow-up of 19.3 months, 2-year overall and disease-free survival were 78.5% and 76.7%, respectively, with grade ≥3 toxicities mainly hematologic and infections comparable to historical controls.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.